NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Hopeforthefuture, bear in mind that there is no evidence that the helmet or any other treatment for that matter, increases the survival time of rGBM patients. OTOH, DCVax-L has a dramatic positive effect on the mOS of those patients. It is quite possible that the mOS of the 64 crossovers is at least 8 months longer than the mOS of the ECAs.

Furthermore, as far as I know, there are no additional treatments that have been shown to act synergistically with the helmet whereas that potential definitely exists for GBM patients treated with DCVax-L (e.g. CIs, polyICLC).

We also don't know how reliable the helmet's survival data is post 2-3 years whereas the 5 year survival data of the DCVax-L treatment arm is not in doubt.